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Abstract 
 
Objective: To review and quantify the association between endogenous and exogenous 
testosterone and prostate specific antigen (PSA) and prostate cancer. 
 
Methods: Literature searches were performed following the PRISMA guidelines. Prospective 
cohort studies that reported data on the associations between endogenous testosterone and 
prostate cancer, and placebo controlled randomised trials of testosterone replacement 
therapy (TRT) that reported data on PSA and/or prostate cancer cases were retained. Meta-
analyses were performed using random-effects models with tests for publication bias and 
heterogeneity. 
 
Results: Twenty estimates were included in a meta-analysis which produced a summary 
relative risk of prostate cancer for an increase of 5 nmol/L of testosterone of 0.99 (95% CI 
(0.96, 1.02)) without heterogeneity (I² = 0%). Based on 26 trials, the overall difference in PSA 
levels following onset of use of TRT was 0.10 ng/mL (-0.28, 0.48). Results were similar when 
conducting heterogeneity analyses by mode of administration, region, age at baseline, 
baseline testosterone, trial duration, type of patients and type of testosterone replacement 
therapy. The summary relative risk of prostate cancer as an adverse effect from 11 TRT trials 
was 0.87 (0.30; 2.50). Results were consistent across studies. 
 
Conclusions: Prostate cancer appears to be unrelated to endogenous testosterone levels. 
Testosterone replacement therapy for symptomatic hypogonadism does not appear to 
increase PSA levels nor the risk of prostate cancer development. The current data are 
reassuring although some care is essential until multiple studies with longer follow-up are 
available. 
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Introduction 
Testosterone is important for normal growth, development and maintenance of the prostate 
gland. Testosterone deficiency in aging men has become a topic of increasing interest and 
debate worldwide. Cross-sectional and longitudinal data indicate that testosterone levels are 
reduced progressively with age and that a significant percentage of men aged over 60 years 
have serum testosterone levels that are below the lower limits of young adult men aged 20±
30 years [1-3]. Late onset hypogonadism (LOH) is a clinical and biochemical syndrome 
associated with advancing age and characterized by a deficiency in serum testosterone 
levels, among other signs and symptoms [4, 5]. Late onset hypogonadism may result in 
significant detriment to quality of life and adversely affect the function of multiple organ 
systems. Therefore, there has been a growing awareness of the potential health benefits of 
testosterone therapy for men with testosterone deficiency, including improved sexual desire 
and performance, improved mood, increased muscle mass and strength, decreased fat mass 
and improved bone mineral density [6].  
 
More than 60 years ago, Huggins demonstrated that suppression of testosterone levels 
caused regression of prostate cancer, and it is now commonplace for men with metastatic 
prostate cancer to undergo treatment designed to lower testosterone levels [7]. Many 
urologists are concerned that testosterone replacement therapy may accelerate prostate 
growth not only in benign disease but also in cancer. If lowering testosterone causes prostate 
cancer to regress in men, does elevating testosterone cause prostate cancer to appear? 
 
Prostate cancer is the second most common cancer in men and a high proportion of men 
harbour microscopic foci of prostate cancer [8]. It has been hypothesized that sex hormones 
and androgens in particular might be involved in prostate cancer carcinogenesis. Zaridze and 
co-workers concluded from qualitative analysis that there was little, if any, association 
between serum levels of testosterone and the risk of prostate cancer [9]. A collaborative 
analysis of 18 prospective studies on endogenous sex hormones and prostate cancer 
conducted in 2008 found no associations between the risk of prostate cancer and serum 
concentrations of testosterone, or other sex hormones [10]. Additionally, an increase in 
exogenous testosterone replacement therapies has been encouraged by media attention and 
marketing of new transdermal formulations (patches or gels) for the treatment of LOH. 
Several systematic reviews discussed about the benefits and risks of testosterone treatment 
[11-13], and several meta-analyses tried to quantify these risks [14-16].  
 
This review aims at evaluating the potential relationship between testosterone and prostate 
cancer, and to synthesise all available data regarding the impact of testosterone replacement 
therapy (TRT) on changes in Prostate Specific Antigen (PSA) levels and on the risk of 
development of prostate cancer. Two approaches have been employed, separately for 
endogenous and exogenous testosterone. A meta-analysis of long-term observational data 
has been retained for quantifying the relationship between endogenous levels of testosterone 
and prostate cancer. A meta-analysis of short-term placebo-controlled randomised trials of 
testosterone supplementation and their adverse effects was done in order to test the 
hypothesis of a rapid acceleration of prostatic cancer development with the use of 
exogenous testosterone. 
 
Methods 
A systematic literature search and quantitative analysis was planned, conducted and 
reported following PRISMA guidelines [17]. Published reports were obtained from the 
Cochrane library and PUBMED. Other sources were found in the reference lists of the 
retrieved articles and preceding reviews on the topic. There was no restriction on 
geographical location of studies, but only articles published in English were considered. 
Articles were first screened by title and abstract. Then, full copies of the potentially relevant 
articles were retrieved and read by at least two co-authors. Data were then extracted in a 
predefined database by one author, and double-checked by the statistician who performed 
the analyses. 
 
Endogenous testosterone 
 
The Endogenous Hormones and Prostate Cancer Collaborative Group (EHPCCG) published 
a pooled analysis of 18 prospective studies [10]. Original articles from each study identified 
by the EHPCCG, including those not included in the pooled analysis, were retrieved. Then, a 
literature search was performed in May 2015 for the period 2007-2015 in order to collect 
articles published after the EHPCCG pooled analysis. 
 
Only prospective studies including cohort studies, nested case-control studies, case-cohort 
studies and control arms of randomized controlled trials were eligible. Articles had to report 
risk estimates for prostate cancer according to baseline serum testosterone levels. The list of 
keywords for literature search is reported in supplementary figure (Figure S1). A dose-
response meta-analysis was conducted for the calculation of the summary relative risk (SRR) 
corresponding to an increase of 5 nmol/L of baseline testosterone [18]. A change of 5nmol/L 
corresponds broadly to the average difference between tertiles of population in the studies 
included in the present meta-analysis. Heterogeneity analyses were performed in order to 
investigate potential sources of variation between studies: by region (USA, Europe), age at 
baseline (cut-off 65 years) and follow-up duration (cut-off 10 years). 
 
The following variables were extracted: first author name and year of publication, country, 
baseline age, baseline testosterone (nmol/L), follow-up duration and for each quantile of 
testosterone, mean or median testosterone (nmol/L), number of subjects, person-years, 
relative risk estimate and 95% confidence interval (CI). 
 
Exogenous testosterone 
The meta-analyses focused on the potential associations between use of TRT and 1) 
changes in PSA level and 2) incidence of prostate cancer. Placebo-controlled, randomized 
trials reporting statistics on these two outcomes were eligible for the meta-analysis. The 
included outcome for change in PSA level could have been PSA level at baseline and end of 
study or change in PSA level during the study. For incidence of prostate cancer, it could have 
been number of prostate cancer occurring in each treatment arm, incidence rate, or odds-
ratio comparing treatment arm to control group. 
 
The following variables were extracted: first author name and year of publication, country, 
baseline age, baseline testosterone (nmol/L), follow-up duration, type of subjects (healthy or 
other), drug name and dose, mode of administration, number of participants by group, PSA 
level related data and number of prostate cancer cases by group.  
 
Increase in PSA level 
 
Data were abstracted on change in PSA level and its corresponding standard deviation. For 
studies that reported only baseline and end of study PSA with corresponding standard 
deviation, the variance of the average difference was estimated with the variance of PSA 
baseline and PSA end of study using a correlation factor to account for auto-correlation. This 
correction factor was calculated using data from the Prostate, Lung, Colorectal and Ovarian 
(PLCO) cancer screening trial [19]. Detailed information about this correction factor are 
available in the Supplementary methods. 
 
Heterogeneity analyses were undertaken by region (USA, Europe), mode of administration 
(transdermal, intramuscular, oral), type of patients (healthy subjects, subjects with pre-
existing comorbidities), age at baseline (cut-off 65 years), trial duration (cut-off one year) and 
baseline testosterone (cut-off 11 nmol/L). This cut-off was chosen because it was the 5th 
percentile of the serum testosterone distribution of healthy men aged 35-44 [20]. An analysis 
by dose of testosterone could not be undertaken because of differences in modes and 
frequencies of administrations. 
 
Prostate cancer 
 
Following Cochrane review guidelines [21], studies reporting zero cases in both intervention 
and control arms were excluded. Since these studies deal with rare events, odds ratios and 
corresponding 95% CI were calculated applying a correction of 0.5 to all entries. The same 
heterogeneity analyses as for the TRT and PSA were conducted.  
 
Meta-analysis 
 
Meta-analyses were undertaken with restricted maximum likelihood (REML) random effects 
models [22]. The 95% confidence intervals of summary estimates were calculated using a t-
distribution. 
 
To summarize incidence of prostate cancer from TRT trials, because of very low event rates, 
the Mantel-Haenszel method was used [23, 24]. 
+HWHURJHQHLW\DFURVVVWXGLHVZDVHYDOXDWHGE\WKH&RFKUDQ¶V4VWDWLVWLFDQGZLWK+LJJLQV¶,ð
[25]. Publication bias was investigated using the funnel plot and Macaskill test [26], Begg test 
[27], and Egger test [28]. The meta-analyses were carried out in programming language R 
(version 3.0.0, GNU General Public License, 2013) and package metafor [29]. In addition to 
the heterogeneity analyses described above, sensitivity analyses, excluding one study at a 
time, were performed in order to evaluate the influence of individual studies on the overall 
result (leave-one-out). In sensitivity analysis, the association between endogenous 
testosterone and prostate cancer was also computed as a high versus low meta-analysis 
comparing the risk in the highest quantile of PSA to the lowest quantile of PSA. 
 
 
Results 
Endogenous testosterone levels and prostate cancer  
 
The literature search yielded 151 articles. After title review, 27 articles were selected for 
abstract reading. Twenty studies reporting risk of prostate cancer for different levels of PSA 
were identified (Supplementary figure 1). Two studies provided data on testosterone levels to 
EHPCCG, but did not publish these data independently and could not be included in the 
present work [30, 31]. Data from the Janus databank were used twice in the pooled analysis, 
but the two datasets were independent and were considered as two separate studies [32, 
33]. Stattin and colleagues published data from three cohorts and risk estimates were 
included separately [32]. Studies included in the meta-analysis included 5,623 prostate 
cancer cases and 14,604 controls. Average follow-up was 10 years (Table 1). 
 
The summary relative risk (SRR) for an increase of 5 nmol/L of serum testosterone was 0.99 
(95% CI (0.96; 1.02)). There was no evidence of heterogeneity (I² = 0%) nor of publication 
bias (pBegg = 0.87; pEgger = 0.17; pMacaskill = 0.69) (Figure 1). In addition, visual inspection of the 
funnel plot did not suggest publication bias. The leave-one-out analysis showed that no study 
taken individually had a big influence on the SRR. The heterogeneity analyses showed that 
results were consistent by region, age at baseline and duration of follow-up. A sensitivity 
analysis based on high versus low serum testosterone approach yielded similar results: 
SRR=0.98 (95% CI (0.88; 1.09)) (Table 3). 
 
Testosterone supplementation and increase in PSA levels 
 
Twenty-seven placebo-controlled trials were included in the quantitative analysis of 
testosterone supplementation and its adverse effects. Twenty-seven studies reported data 
on PSA levels, and 11 reported data on incidence of prostate cancer (Supplementary Figure 
2). This involved a total of 2213 subjects in the intervention groups, and 1456 subjects in the 
placebo control groups. The median trial duration was 196 days. In 13 trials, TRT was 
administered transdermally (patch or gel), in nine trials intramuscularly, and in four trials 
orally. Thirteen studies were conducted in the United States, 10 in Europe, two in Asia and 
one in Australia. Fifteen trials were carried out in healthy subjects and 11 in patients with pre-
existing comorbidities such as diabetes mellitus or metabolic syndrome (Table 2). 
 
A total of 27 studies produced unique estimates of the change in PSA levels after onset of 
use of testosterone replacement therapy. One of them did not provide variability data and 
was excluded from the main analysis [34]. The summary difference (SES) in PSA levels was 
found to be SES=0.10 ng/mL (95% CI (-0.28; 0.48); (figure 2). There was no evidence of 
heterogeneity (I2=0%). Tests of publication bias produced conflicting results: while visual 
inspection of the funnel plot did not suggest publication bias and while there was no evidence 
of publication bias from the Begg test (pBegg=0.88) and the Macaskill test (pMacaskill=0.52), the 
Egger test was statistically significant (pEgger=0.01). In a sensitivity analysis, the study with no 
measure of dispersion was added, assuming a standard deviation of 1 in intervention and 
control arms; it did not modify the SES: 0.10 ng/mL (95% CI (-0.27; 0.48)). 
 
Heterogeneity analyses revealed that the increase in PSA levels following testosterone 
supplementation were slightly higher among Americans (SES = 0.34 ng/ml) than in 
(XURSHDQV6(6 QJPOLQROGHUVXEMHFWV6(6IRU\HDUV QJPOYV
ng/ml for under 65 years at baseline) and among subjects with high levels of testosterone 
(SES = 0.25 ng/ml for baseline testosterone > 11 ng/mL vs. 0.07 ng/ml for others). However, 
these differences were small and did not reach statistical significance. TRT had a similar 
effect of PSA levels in healthy subjects and others. Duration of the trial had no influence on 
the results. There were not enough studies in the analysis by subtype of testosterone to draw 
conclusions (Table 3). 
 
Testosterone supplementation and risk of prostate cancer 
A total of 11 studies produced unique estimates of the risk of prostate cancer diagnosis 
associated following the use of testosterone replacement therapy (Table 2). The Summary 
Odds Ratio (SOR) was 0.87 (95% CI (0.30; 2.50)) based on 20 prostate cancer cases. There 
was no evidence of heterogeneity (I2=0%) nor publication bias (pBegg=0.82, pEgger=0.26, 
pMacaskill=0.70 (Figure 3). From the leave-one-out analysis, no study had a big impact on the 
SOR. In a sensitivity analysis, prostate cancer cases diagnosed during open-label extensions 
of studies were included. Three new cases of prostate cancer and two additional studies 
were included in this analysis [34, 35]; these did not modify the results: SOR = 0.84 (95% CI 
(0.31; 2.25)). 
 
Results of heterogeneity analyses should be interpreted with caution because of the low 
number of studies included in each analysis, resulting in poor statistical power. None of the 
subgroup analysis showed a statistically significant increased risk of prostate cancer (Table 
3). 
 
Discussion 
Endogenous Testosterone 
Serum androgens in general and testosterone in particular have been widely studied in 
relationship with prostate cancer development as they are potential risk factors for this 
disease. Results of individual studies often lacked of statistical power and were sometimes 
inconsistent with each other. In 2008, the EHPCCG conducted a large pooled analysis in 
order to summarize the existing evidence on this topic [10]. No association was found 
between levels of sex hormones, including testosterone, and incidence of prostate cancer. 
 
The present work included four new studies compared to the earlier pooled analysis. In 
addition, this meta-analysis used a dose-response modelling instead of using a high vs. low 
approach. Our results confirmed those of the EHPCCG pooled analysis, i.e. high serum 
testosterone levels were not associated with increased risk of prostate cancer in prospective 
observational studies. Heterogeneity analyses showed that results were similar by region, 
age at baseline and duration of follow-up. 
 
Exogenous testosterone 
 
Testosterone supplementation for the treatment of hypogonadism is controversial. With the 
direct-to-consumer advertising and very rapid increase in testosterone prescription, some 
authors suggested that hypogonadism was largely disease mongering [36]. There is some 
evidence to suggest improved libido, muscle mass or mood [6], but also several concerns 
about the possible stimulation of prostate growth. 
 
There was no evidence of increased PSA levels after testosterone supplementation from an 
analysis of data from 27 placebo controlled, randomized trials. No major source of 
heterogeneity was identified. From the 11 trials reporting prostate cancer cases, the meta-
analysis found no evidence of an increased risk of prostate cancer associated with 
testosterone replacement therapy. 
 
A limitation to this analysis is the relative short duration of the trials with most of the trials 
lasting less than one year. This was an issue mainly for the prostate cancer analysis. With 
such a short follow-up, few prostate cancers cases were reported, resulting in low statistical 
power. The analysis restricted to studies with a follow-up greater than one year did not show 
an increase risk of prostate cancer nor a change in PSA level. A possible publication bias 
might be taken into consideration, as more than half of the articles that were found otherwise 
eligible, were excluded because they did not report enough data. 
 
These results were consistent with data reported in previous meta-analyses. Cui and 
colleagues [14], using data from eight trials, concluded that TRT did not promote prostate 
cancer development; furthermore, using data from 12 trials, they found no difference in 
abnormal PSA levels between treated and un-treated patients. Fernandez-Balsells and 
colleagues reported the SRR for prostate cancer to be 0.79 (95% CI (0.28; 2.28)), based on 
five studies [16] &DORI DQG FROOHDJXHV FRQFOXGHG WKDW WKH QXPEHU RI ³SURVWDWH HYHQWV´
(biopsies, cancers, increase in IPSS > 4, PSA > 4 ng/mL or PSA increment > 1.5 ng/mL 
during treatment, and acute urinary retention) was higher in the intervention group than in the 
SODFHERJURXSSRROHG25&,+RZHYHUWKHULVNRI³SURVWDWHHYHQWV´
was essentially limited to prostate biopsies (pooled OR 1.87), and prostate cancer alone was 
not significantly higher (pooled OR 1.09 (95% CI 0.48; 2.49)) [15]. 
 
It could also be hypothesised that the potential impact of testosterone therapy on prostate 
growth be limited to older men, or individuals with initially low level of testosterone, or vary 
according to route of administration. However, none of the heterogeneity analysis confirmed 
these hypotheses. 
 
Conclusions 
The earlier work of the EHPCCG showed no association between serum testosterone levels 
and risk of prostate cancer [10]. More recent studies confirmed this lack of association; no 
individual study found any increased or decreased risk of prostate cancer among men with 
high levels of testosterone compared to lower levels. Meta-analysis showed no association 
between testosterone levels and prostate cancer risk. Prostate cancer development appears 
unrelated to endogenous serum testosterone levels. 
 
The available data do not support an increase in the risk of prostate cancer associated with 
testosterone replacement therapy nor do they support a change in PSA levels when 
testosterone replacement therapy is used. Testosterone replacement therapy for 
symptomatic hypogonadism does not appear to increase PSA levels nor the risk of prostate 
cancer development. The current data are reassuring although some care is still essential 
until multiple studies with longer follow-up are available. 
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Legends to Figures 
 
Figure 1: Serum testosterone and risk of prostate cancer (Dose-response meta-analysis) 
Figure 2: Testosterone Replacement Therapy (all forms) and absolute difference in PSA 
levels. 
Figure 3: Testosterone Replacement Therapy risk of prostate cancer 
 
Table 1. Description of studies included in the endogenous testosterone levels and prostate cancer analysis 
Author, year (acronym) [reference] Country Design Cases Non-cases Age 
Baseline 
Testosterone  
(nmol/L) 
Follow-
up 
(years) 
Barrett-Connor, 1990 (RBS) [37] USA Cohort 57 944 63 18.0 14 
Chen, 2003 (CARET) [38] USA NCC 300 300 61 14.8 3 
Daniels, 2010 (OFM) [39] USA Cohort 275 1750 73 14.3 4.7 
Dorgan, 1998 (ATBC) [40] Finland NCC 116 228 61 20.3 4.1 
Gann, 1996 (PHS) [41] USA NCC 222 390 62 16.4 6.3 
Gill, 2010 (MEC) [42] USA NCC 452 936 69 18.9 1.9 
Heikkila, 1999 (FMC) [43] Finland NCC 166 300 58 25.1 24 
Hsing, 1993 (CLUE I) [44] USA NCC 98 98 65 15.5 13 
Muller, 2012 (REDUCE) [45] USA Placebo arm of RCT 679 2576 63 15.8 4 
Nomura, 1996 (JHCS) [46] USA NCC 141 141 62 18.7 22 
Ozasa, 2004 (JACC) [47] Japan NCC 40 101 69 15.8 10 
Parsons, 2005 (BLSA) [48] USA Cohort 88 706 52 16.0 18.5 
Platz, 2005 (HPFS) [49] USA NCC 448 448 65 16.8 5 
Severi, 2006 (MCCS) [50] Australia Case-cohort 518 1859 55 15.7 8.7 
Stattin, 2004 (NBSBWG/HHS) [32] Finland NCC 84 291 51 20.7 10.8 
Stattin, 2004 (NBSBWG/NSHDC) [32] Sweden NCC 86 337 59 30.7 3.5 
Stattin, 2004 (NBSBWG/Janus) [32] Norway NCC 534 1599 47 23.6 16.7 
Travis, 2007 (EPIC) [51] Europe NCC 533 533 61 15.7 3.4 
Vatten, 1997 (Janus)[33] Norway NCC 59 180 59 19.9 10 
Weiss, 2008 (PLCO) [52] USA NCC 727 887 66 17.2 13 
ATBC: Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; BLSA: Baltimore Longitudinal Study of Aging; CARET: Carotene and Retinol Efficacy Trial; CLUE I: CLUE Study; 
EPIC: European Prospective Investigation into Cancer and Nutrition; FMC: Finnish Mobile Clinic Health Examination Survey; HHS: Helsinki Heart Study; NBSBWG: Nordic Biological 
Specimen Biobank Working Group; HPFS: Health Professionals Follow-up Study; JACC: Japan Collaborative Cohort Study; Janus: Janus Serum Bank; JHCS: Japan ± Hawaii 
Cancer Study; MCCS: Melbourne Collaborative Cohort Study; MEC: Multiethnic cohort; NSHDC: Northern Sweden Health and Disease Cohort; OFM: Osteoporotic fractures in men; 
3+6 3K\VLFLDQV¶ +HDOWK 6WXG\ 3/&2 3URVWDWH /XQJ &RORUHFWDO DQG 2YDULDQ FDQFHU VFUHHQLQJ WULDO 5%6 5DQFKR Bernardo Study; REDUCE: Reduction by Dutastenide of 
Prostate cancer events trial  
Table 2. PSA and prostate cancer outcomes in trials of testosterone replacement therapy included in meta-analysis 
Study Mode 
Duration 
(days) 
Subjects 
(Intervention) 
Subjects 
(Control) 
Country Study population 
Ag
e 
Baseline testosterone 
(nmol/L) 
Amory, 2004 [53] IM 1095 24 24 USA Healthy 71 10.2 
Aversa, 2010 [54] IM 365 40 10 Italy MS/T2DM 58 8.5 
Basaria, 2010 [55] TD 180 106 103 USA Limitations in mobility 74 8.4 
Behre, 2012 [56] TD 180 183 179 Europe Healthy 62 10.5 
Bhasin, 1998 [57] TD 84 20 21 USA HIV infected 39 8.1 
Caminiti, 2009 [58] IM 84 35 35 Italy CHF 71 7.6 
Chiang, 2009 [59] 
TD 90 20 20 Taiwan 
Healthy 
47.
5* 0.6 
Emmelot-Vonk, 2008 
[60] 
oral 180 113 
110 The 
Netherlan
ds 
Healthy 67 
10.7 
Ferrando, 2002 [61] IM 180 7 5 USA Healthy 68 12.6 
Hackett, 2013 [62] IM 210 92 98 UK T2DM 61 9.1 
Hildreth, 2013 [63] TD 365 111 56 USA Healthy 67 10.3 
Holmäng, 1993 [64] Oral 240 11 12 Sweden Healthy 52 16.4 
Jones, 2011 [65] TD 365 108 112 Europe MS/T2DM 60 9.4 
Kalinchenko, 2010 
[66] IM 210 113 71 Russia 
MS 52 
7.0 
Kaufman, 2011 [35] TD 182 234 40 USA Healthy 54 10.0 
Kenny, 2001 [67] TD 365 34 33 USA Healthy 76 13.5 
Kenny, 2004 [68] IM 84 6 5 USA Early cognitive decline 80 14.1 
Kenny, 2010 [69] TD 365 53 46 USA Osteoporosis/frailty 77 13.8 
Malkin, 2006 [70] TD 365 37 39 UK CHF 64 13.0 
Marks, 2006 [71] IM 180 22 22 USA Healthy 69 8.2 
Morgentaler, 2014 
[34] TD 182 234 40 USA 
Healthy 54 
8.5 
Nair, 2006 [72] TD 730 30 32 USA Healthy 67 13.2 
Park, 2003 [73] 
Oral 90 33 6 
South 
Korea 
Healthy NR 
9.2 
Sih, 1997 [74] IM 365 17 15 USA Healthy 68 9.2 
Snyder, 1999 [75] 
TD 1095 54 54 USA 
Bone mineral density < 
1.26 g/cm² 
73 
12.8 
Srinivas-Shankar, 
2010 [76] TD 180 130 132 UK 
Frailty 74 
10.9 
Steidle, 2003 [77] TD 90 307 99 USA Healthy 58 8.1 
Wittert, 2003 [78] Oral 365 39 37 Australia Healthy 69 16.3 
TD=Transdermal (includes testosterone patches or testosterone gels); IM = Intramuscular; NR=Not Reported; MS = Metabolic syndrome; T2DM = type 2 diabetes mellitus; T NOS= Testosterone not otherwise specified; TU = Testosterone 
undecanoate; TE = testosterone enanthate; TC = testosterone cypionate; CHF = chronic heart failure; BPH = benign prostate hypertrophy; * range 20-75 
 
  
Table 3: heterogeneity analyses 
 Endogenous testosterone TRT PSA TRT PCA 
Analysis 
# 
Studies 
Summary estimate RR 
per 5 nmol/L** (95% CI) 
# 
Studies 
Summary estimate 
PSA: absolute 
difference (ng/mL) 
(95% CI) 
# 
Studies 
Summary estimate 
MH-OR (95% CI) 
Main analysis (all studies) 20 0.99 (0.96; 1.02) 26 0.10 (-0.28; 0.48) 11 0.87 (0.30; 2.50) 
Sensitivity analysis: high vs. low serum 
testosterone approach 
20 0.98 (0.88; 1.09) 
    
Sensitivity analysis: studies from EHPCCG 16 0.97 (0.93; 1.01)     
Sensitivity analysis: include study with no SD 
assuming SD = 1 [34] 
  27 0.10 (-0.27; 0.48)   
Sensitivity analysis: include cases occurring 
during open-label phase, or additional follow-
up, etc 
    13 0.84 (0.31; 2.25 
Studies conducted in the USA 11 1.01 (0.98; 1.05) 13 0.34 (-0.41; 1.10) 7 1.32 (0.33; 5.25) 
Studies conducted in Europe 7 0.95 (0.90; 1.01) 10 0.09 (-0.58; 0.76) 4 0.24 (0.01; 8.77) 
Age at baseline < 65 years 15 0.99 (0.95; 1.02) 10 0.11 (-0.47; 0.69) 3 2.04 (0.01; 461.7) 
$JHDWEDVHOLQH\HDUV 5 1.02 (0.93; 1.11) 15 0.30 (-0.41; 1.00) 8 0.74 (0.22; 2.54) 
Short Follow-up * 12 0.99 (0.96; 1.03) 15 0.07 (-0.41; 0.55) 7 0.58 (0.14; 2.41) 
Long Follow-up * 8 1.00 (0.93; 1.09) 11 0.17 (-0.57; 0.91) 4 2.15 (0.12; 37.46) 
%DVHOLQH7HVWRVWHURQHQPRO/   17 0.07 (-0.37; 0.51) 8 0.75 (0.22; 2.54) 
Baseline Testosterone > 11 nmol/L   9 0.25 (-0.70; 1.20) 3 2.05 (0.01; 469.8) 
Studies conducted in healthy subjects   15 0.08 (-0.43; 0.58) 7 0.63 (0.17; 2.39) 
Studies conducted in subjects with 
comorbidities 
  11 0.14 (-0.52; 0.81) 4 2.98 (0.07; 122.67) 
Administration: transdermal   13 0.20 (-0.41; 0.81) 7 2.57 (0.31; 21.16) 
Administration: intramuscular   9 0.21 (-0.56; 0.98) 3 0.61 (0.03; 11.38) 
Administration: oral   4 -0.21 (-1.40; 0.98) 1 NR 
Testosterone undecanoate   8 -0.12 (-0.78; 0.55) 2 NR 
Testosterone enhanthate   4 0.61 (-1.42; 2.63) 2 NR 
Testosterone: other and unspecified   13 0.20 (-0.41; 0.81) 7 2.57 (0.31; 21.16) 
TRT: testosterone replacement therapy; MH-OR: Mantel-Haenzel odds ratio; *Short Follow-XS\HDUVIRUFRKRUWVWXGLHV\HDUIRUUDQGRPL]HG
controlled trials; *Long Follow-up: > 10 years for cohort studies, >1yr year for randomized controlled trials; **except for the high vs. low analysis
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Supplementary figures 
 
20 studies included in 
meta-analysis
151 articles identified
through database searching
27 articles screened
8 full-text articles assessed
for eligibility
4 articles meeting eligibility
criteria
4 ineligible articles 
excluded
19 articles identified with
EHPCCG pooled analysis
3 ineligible articles 
excluded
16 articles meeting 
eligibility criteria
PubMed keywords:  ?ƐĞƌƵŵƚĞƐƚŽƐƚĞƌŽŶĞ ? ? ?ƉƌŽƐƚĂƚĞĐĂŶĐĞƌ ? ? ?ĐŽŚŽƌƚ ? ? ?Ɖ ŽƐƉĞĐƚŝǀĞ ? ?
 ?ƌĂŶĚŽŵŝǌĞĚĐŽŶƚƌŽůůĞĚƚƌŝĂů ?
 
Figure S1: Literature search flowchart for study selection: endogenous testosterone 
and prostate cancer 
 
Figure S2: Literature search flowchart for study selection: Exogenous testosterone, 
Prostate Specific Antigen, and prostate cancer 
Figure 1b: PRISMA for Exogenous testosterone and prostate cancer 
28 studies included in quantitative synthesis:
27 studies in the PSA analysis
11 studies in the prostate cancer incidence
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39 records excluded81 records screened
17 full-text articles excluded
42 full-text articles 
assessed for eligibility
269 records identified through database searching and published reviews and 
meta-analyses
Supplementary methods: PLCO Study 
Most studies reported only baseline (BPSA) and end of study (EPSA) PSA with 
corresponding standard deviations, but not the average difference ƩPSA) and 
corresponding standard deviation. The average difference was therefore estimated 
as the difference of the average PSA at the end of study minus the average PSA at 
baseline. However, it would have been erroneous to consider the two measurements 
of PSA as independent in the computation of the variance of the difference and we 
needed to estimate the covariance between measurements. The following formula 
was used to compute the variance of the difference:  ܸܽݎሺ ?ܲܵܣሻ ൌ ݒܽݎሺܤ௉ௌ஺ሻ ൅ ݒܽݎሺܧ௉ௌ஺ሻ െ  ?ݎ ?ሺܸܽݎሺܤ௉ௌ஺ሻ כ ݒܽݎሺܧ௉ௌ஺ሻሻ 
The coefficient r represents the correlation between the two measurements. It was 
computed from the PLCO study with dataset as of August 2012 [1].  
Interpretation of changes in PSA (particularly in low ranges i.e.  4 ng/mL) is not 
straightforward and PSA testing has been shown to induce substantial over-diagnosis 
of prostate cancer, mainly due to poor specificity of the test. To help understand the 
occurrence and magnitude of variations of PSA levels in men with initially low levels 
of PSA, a detailed analysis of subjects participating in the intervention arm of the 
Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Cancer Screening Trial who 
had DQLQLWLDO36$OHYHO 4 ng/mL was conducted. 
Data were abstracted from the PLCO study [1] on all men in the intervention arm 
with two tests performed in a period of less than two years and with an initial result 
of the first test  4 ng/mL. The range of variation of the second test compared to 
initial level was examined.  
Among the 38,340 men participating to the intervention arm, 31,286 men had two 
PSA tests performed within two years and with an initial value  4 ng/mL. From 
these data, a correlation coefficient r of 0.64 was estimated and used in our analysis.  
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